Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD113 vs Atomoxetine in OSA with Hypertension
NCT04905979Phase 2Completed
- Sponsor
- Apnimed, Inc.
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AD113 in obstructive sleep apnea (OSA), sponsored by Apnimed, Inc.. Started Jul 2021; status: completed.
02
Drugs
AD113
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04905979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905979.